Evidence map›Paper›PMID 33472091›Full record

ArticleCancer letters2021

Prolactin synergizes with canonical Wnt signals to drive development of ER+ mammary tumors via activation of the Notch pathway.

Kathleen A O'Leary, Debra E Rugowski, Michael P Shea, Ruth Sullivan, Amy R Moser, Linda A Schuler

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Prolactin: The Third Hormone in Breast Cancer.Frontiers in endocrinology · 2022
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kathleen A O'LearyDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA.
Debra E RugowskiDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA.
Michael P SheaDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA; Molecular and Environmental Toxicology Program, University of Wisconsin-Madison, Madison, WI, USA.
Ruth SullivanDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, WI, USA.
Amy R MoserDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, WI, USA.
Linda A SchulerDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, WI, USA. Electronic address: linda.schuler@wisc.edu.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Molecular & Environmental Toxicology Pre-& Postdoctoral Training ProgramT32ES007015 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI CHRISTOPHER A BRADFIELD · 1985 to 2026
$11.5M
Matrix density promotes pro-tumorigenic hormone actions in breast cancerR01CA179556 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PONIK, SUZANNE MARIE, SCHULER, LINDA A. · 2014 to 2024
$4.9M
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomasR01CA157675 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SCHULER, LINDA A. · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA157675NCI NIH HHS R01 CA179556NIEHS NIH HHS T32 ES007015
6 · The paper itself

Abstract

Prolactin (PRL) cooperates with other factors to orchestrate mammary development and lactation, and is epidemiologically linked to higher risk for breast cancer. However, how PRL collaborates with oncogenes to foster tumorigenesis and influence breast cancer phenotype is not well understood. To understand its interactions with canonical Wnt signals, which elevate mammary stem cell activity, we crossed heterozygous NRL-PRL mice with Apc

Indexed as

Adenomatous Polyposis Coli ProteinAnimalsCell NucleusCell ProliferationFemaleMammary Neoplasms, ExperimentalMiceMice, TransgenicMutagensProlactinReceptors, NotchWnt Signaling PathwayAdenomatous Polyposis Coli Proteinadenomatous polyposis coli protein, mouseMutagensProlactinReceptors, NotchAPCBreast cancerNotchProlactinWntβ-catenin

Identifiers

PMID33472091
PMCPMC7995738
OpenAlexW3126074184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.